Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | +3.90% | -9.66% | -14.52% |
Apr. 22 | Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder | MT |
Apr. 12 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.24M |
---|---|---|---|---|---|
Net income 2024 * | -6M | Net income 2025 * | -9M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.77
x | P/E ratio 2025 * |
-0.97
x | Employees | 6 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.96% |
1 day | -5.52% | ||
1 week | -9.41% | ||
Current month | -9.41% | ||
1 month | +32.76% | ||
3 months | +26.24% | ||
6 months | -32.16% | ||
Current year | -17.20% |
Managers | Title | Age | Since |
---|---|---|---|
Bankole Johnson
FOU | Founder | 64 | 10-10-31 |
Cary Claiborne
CEO | Chief Executive Officer | 64 | 21-11-01 |
Joseph Truluck
DFI | Director of Finance/CFO | 46 | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jack W. Reich
LAW | General Counsel | - | 20-05-18 |
Cary Claiborne
CEO | Chief Executive Officer | 64 | 21-11-01 |
Tony Goodman
COO | Chief Operating Officer | 60 | 17-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 1.58 | +2.60% | 150 590 |
24-05-07 | 1.54 | -5.52% | 95,916 |
24-05-06 | 1.63 | -4.12% | 224,307 |
24-05-03 | 1.7 | -5.03% | 107,846 |
24-05-02 | 1.79 | +1.70% | 245,299 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.20% | 6.24M | |
+10.44% | 107B | |
+0.82% | 106B | |
+8.15% | 23.47B | |
-13.89% | 21.9B | |
-6.13% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- ADIL Stock